Compare Neurocrine Biosciences Inc (NBIX) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B), while Invesco S&P 500 High Div Low Volatility ETF trades at $48.77 (market cap $3.14B). The key difference: Neurocrine Biosciences Inc is far larger — about 4.6× Invesco S&P 500 High Div Low Volatility ETF's market cap, and Invesco S&P 500 High Div Low Volatility ETF is more actively traded (1,461,349 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Invesco S&P 500 High Div Low Volatility ETF for 125 Days on average.
| NBIX | SPHD | |
|---|---|---|
Market Cap | $14.36B | $3.14B |
Volume | 1,237,180 | 1,461,349 |
Sector | Health | — |
52-Week High | $185.50 | $53.55 |
52-Week Low | $123.10 | $46.96 |
Typical Hold Time | 23 Days | 125 Days |
Enterprise Value | $14.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
SPHD trades at $48.19, down 0.58% on the day, with a bearish technical signal driven by moving averages. The ETF focuses on high-dividend, low-volatility S&P 500 stocks, offering monthly income but facing criticism for weaker total returns compared to peers like SCHD. Recent dividends of $0.20 and $0.21 were declared for 2026, emphasizing its income-oriented strategy.
Outlook is cautious due to underperformance risks and lack of quality filters in stock selection. Opportunities include reliable monthly dividends for retirees, but risks involve yield traps and market volatility. Investors should weigh income needs against growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
